Pacira BioSciences, Inc. (PCRX)
Automate Your Wheel Strategy on PCRX
With Tiblio's Option Bot, you can configure your own wheel strategy including PCRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PCRX
- Rev/Share 15.1869
- Book/Share 17.2564
- PB 1.5026
- Debt/Equity 0.797
- CurrentRatio 2.4146
- ROIC -0.0841
- MktCap 1200680871.0
- FreeCF/Share 3.4446
- PFCF 7.5325
- PE -11.568
- Debt/Assets 0.4011
- DivYield 0
- ROE -0.1294
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | PCRX | Truist | Sell | Hold | $8 | $25 | Jan. 30, 2025 |
News
Pacira BioSciences, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – PCRX
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).
Read More
Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PCRX
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130970&wire=1 or contact Joseph E. Levi, Esq.
Read More
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Pacira BioSciences, Inc.
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2023 to August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 14, 2025.
Read More
Why Pacira (PCRX) is a Top Momentum Stock for the Long-Term
Published: February 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
PARSIPPANY, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its fourth quarter and year ended December 31, 2024 financial results after the close of the U.S. markets on Thursday February 27, 2025.
Read More
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Pacira BioSciences, Inc. to Contact the Firm Today!
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Read More
Investors in Pacira BioSciences, Inc. Should Contact The Gross Law Firm Before March 14, 2025 to Discuss Your Rights - PCRX
Published: February 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX). Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130774&wire=1 or contact Joseph E. Levi, Esq.
Read More
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, Feb. 19, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Read More
Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130761&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - PCRX
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ:PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
PCRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Pacira BioSciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX) and certain of its officers.
Read More
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130642&wire=1 or contact Joseph E. Levi, Esq.
Read More
Pacira BioSciences, Inc. Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
LOS ANGELES, CA / ACCESS Newswire / February 19, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between August 2, 2023 to August 8, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before March 14, 2025.
Read More
PCRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Pacira BioSciences, Inc. to Contact the Firm Today!
Published: February 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Read More
Levi & Korsinsky Reminds Pacira BioSciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 – PCRX
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130379&wire=1 or contact Joseph E. Levi, Esq.
Read More
Pacira BioSciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 14, 2025 to Discuss Your Rights - PCRX
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130423&wire=1 or contact Joseph E. Levi, Esq.
Read More
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the “Company”) (NasdaqGS: PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - PCRX
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Shareholders That Lost Money on Pacira BioSciences, Inc. (PCRX) Should Contact Levi & Korsinsky About Pending Class Action - PCRX
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130308&wire=1 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A LEADING LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”), of the important March 14, 2025 lead plaintiff deadline.
Read More
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) for violations of the federal securities laws on behalf of investors who purchased or acquired Pacira common stock between August 2, 2023 to August 8, 2024, inclusive (the “Class Period”).
Read More
PCRX Stockholders Have Opportunity to Lead Pacira BioSciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Published: February 18, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ:PCRX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period").
Read More
Lost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 18, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024.
Read More
Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc. (PCRX)
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130136&wire=1 or contact Joseph E. Levi, Esq.
Read More
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW ORLEANS, LA / ACCESS Newswire / February 17, 2025 / Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS:PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the "Class Period").
Read More
Contact Levi & Korsinsky by March 14, 2025 Deadline to Join Class Action Against Pacira BioSciences, Inc. (PCRX)
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130112&wire=1 or contact Joseph E. Levi, Esq.
Read More
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
Published: February 17, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 17, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Lost Money on Pacira BioSciences, Inc. (PCRX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 17, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 17, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pacira-biosciences-inc-lawsuit-submission-form?prid=130056&wire=1 or contact Joseph E. Levi, Esq.
Read More
About Pacira BioSciences, Inc. (PCRX)
- IPO Date 2011-02-03
- Website https://www.pacira.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Frank D. Lee
- Employees 788